Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial;Glukosesenkende Therapie bei Typ-2-Diabetes: Neue Hoffnung nach der EMPA-REG-Wirkungsstudie

Herz

Volumn 41, Issue 3, 2016, Pages 208-216

  Schernthaner, G ^a   Schernthaner, G H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular disease; EMPA REG outcome; Glucose lowering therapy; PROactive; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GLUCOSE LOWERING THERAPY; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; MEDICAL PROCEDURES; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; RISK FACTOR; RISK REDUCTION; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; EVIDENCE BASED MEDICINE; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84963655900     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-016-4427-3     Document Type: Article

References (71)

1. Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from aCCORD, aDVaNCE, VaDT, UKPDS, PROactive, and NICE-SUGaR. Wien Med Wochenschr 160:8–19
2. Gerstein HC, Miller ME, Byington RP et al (2008) Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
3. Patel A, MacMahon S, Chalmers J et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
4. Duckworth W, Abraira C, Moritz T et al (2009) Intensive glucose control and complications in american veterans with type 2 diabetes. N Engl J Med 360:129–139
5. Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta analysis of major trials. Diabetologia 54:25–31
6. Schernthaner GH, Schernthaner G (2005) Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl 240:30–40
7. Preis SR, Hwang SJ, Coady S (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:1728–1735
8. Carstensen B, Kristensen JK, Ottosen P et al (2008) The danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196
9. Lind M, Garcia-Rodriguez LA, Booth GL et al (2013) Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia 56:2601–2608
10. Harding JL, Shaw JE, Peeters A et al (2014) Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997–2010. Diabetes Care 37:2579–2588
11. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222
12. Tancredi M, Rosengren A, Svensson AM et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732
13. Vazquez-Benitez G, Desai JR, Xu S et al (2015) Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care 38:905–912
14. Hirshberg B, Katz A (2013) Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care 36(Suppl 2):253–258
15. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
16. Trial Investigators ORIGIN, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328
17. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
18. White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
19. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
20. Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
21. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
22. Erdmann E, Dormandy JA, Charbonnel B et al (2007) The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49:1772–1780
23. Wilcox R, Bousser MG, Betteridge DJ et al (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865–873
24. Dormandy JA, Betteridge DJ, Schernthaner G et al (2009) Impact of peripheral arterial disease in patients with diabetes results from PROactive (PROactive 11). Atherosclerosis 202:272–281
25. Schneider CA, Ferrannini E, Defronzo R et al (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182–187
26. Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572–2581
27. Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561–1573
28. Schernthaner G (2009) Pleiotropic effects of thiazolidinediones on traditional and nontraditional atherosclerotic risk factors. Int J Clin Pract 63:912–929
29. DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270–1287
30. Schernthaner G, Currie CJ, Schernthaner GH (2013) Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 36(Suppl 2):S155–S161
31. Erdmann E, Charbonnel B, Wilcox RG (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study. Diabetes Care 30:2773–2778
32. Lewis JD, Habel LA, Quesenberry CP et al (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314:265–277
33. Levin D, Bell S, Sund R et al (2015) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58:493–504
34. Chilton R, Tikkanen I, Cannon CP et al (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180–1193
35. Wanner C, Lachin JM, Fitchett DH et al (2015) Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease. J Am Soc Nephrol 26(Suppl B1):1133
36. Nathan DM, Buse JB, Davidson MB et al (2009) (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203
37. Schernthaner G, Barnett AH, Betteridge DJ et al (2010) Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:1258–1269
38. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. position statement of the american diabetes association (aDa) and the european association for the study of diabetes (EaSD). Diabetologia 55:1577–1596
39. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149
40. Schernthaner G, Schernthaner GH (2008) Metformin – From Devil to Angel. In: Pharmacotherapy of Diabetes: New Developments. In: CE Mogensen, editor. Wien: Springer; pp 77–86
41. Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215–224
42. Schernthaner G, Matthews DR, Charbonnel B et al (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068–6076
43. Deacon CF, Lebovitz HE (2015) A comparative review of DPP‑4 inhibitors and Sulphonylureas. Diabetes Obes Metab. doi:10.1111/dom.12610 [Epub ahead of print]
44. Schernthaner G, Barnett AH, Patel S et al (2014) Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years. Diabetes Obes Metab 16:1078–1086
45. Groop PH, Del Prato S, Taskinen MR et al (2014) Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 16:560–568
46. Schernthaner G, Durán-Garcia S, Hanefeld M et al (2015) Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab 17:630–638
47. Schernthaner G, Grimaldi A, Di Mario U et al (2004) GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34:535–542
48. Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908
49. Abdelmoneim AS, Eurich DT, Gamble JM et al (2014) Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 16:22–29
50. Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3:43–51
51. Gross JL, Kramer CK, Leitão CB et al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154:672–679
52. Esposito K, Chiodini P, Bellastella G et al (2012) Proportion of patients at HbA1c target. Diabetes Obes Metab 14:228–233
53. Buse JB, Peters A, Russell-Jones D et al (2015) Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 17:145–151
54. Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508–2515
55. Prager R, Schernthaner G (1983) Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics. Diabetes 32:1083–1086
56. Prager R, Schernthaner G, Graf H (1986) Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab 12:346–350
57. Natali A, Ferrannini E (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434–441
58. Abdul-Ghani MA, Norton L, Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32:515–531
59. Schernthaner G, Mogensen CE, Schernthaner GH (2014) The effects of GLP-1 analogues, DPP‑4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 11:306–323
60. Roussel R, Travert F, Pasquet B et al (2010) Reduction of Atherothrombosis for continued health (REaCH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892–1899
61. Schernthaner G, Schernthaner-Reiter MH (2015) Risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 11:697–699
62. Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579–1588
63. Weir DL, McAlister FA, Senthilselvan A et al (2014) Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2:573–582
64. Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067–2076
65. Fu AZ, Johnston SS, Ghannam A et al (2016) Association between hospitalization for heart failure and Dipeptidyl Peptidase-4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. doi:10.2337/dc15-0764 [Epub ahead of print]
66. Schernthaner G, Cahn A, Raz I (2016) Is the use of DPP‑4 inhibitors associated with an increased risk for heart failure – lessons from SAVOR, EXAMINE and TECOS. Diabetes Care [Epub ahead of print]
67. Udell JA, Bhatt DL, Braunwald E et al (2015) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38:696–705
68. Ou SM, Shih CJ, Chao PW et al (2015) Effects on clinical outcomes of adding Dipeptidyl Peptidase-4 inhibitors versus Sulfonylureas to Metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163:663–672
69. Li J, Tong Y, Zhang Y, Tang L et al (2016) Effects on All-Cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-Analysis of Randomized Controlled Trials. Clin Ther. doi:10.1016/j.clinthera.2015.12.006 [Epub ahead of print]
70. Viscoli CM, Brass LM, Carolei A et al (2014) Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 168:823–829
71. Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. doi: 10.1056/NEJMoa1506930